We rank companies based on fund manager, research analyst and news sentiment
XGN stock icon



About: Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Employees: 179

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

3% more funds holding

Funds holding: 29 [Q3] → 30 (+1) [Q4]

1.48% less ownership

Funds ownership: 40.72% [Q3] → 39.24% (-1.48%) [Q4]

20% less capital invested

Capital invested by funds: $16.7M [Q3] → $13.3M (-$3.36M) [Q4]

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

50% less call options, than puts

Call options by funds: $199 | Put options by funds: $398

Research analyst outlook

We haven’t received any recent analyst ratings for XGN.

Financial journalist opinion